According to Halozyme Therapeutics's latest financial reports the company has a price-to-book ratio of 57.3.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 58.3 | 28.57% |
2022-12-31 | 45.3 | 57.64% |
2021-12-31 | 28.7 | -24.8% |
2020-12-31 | 38.2 | 44.71% |
2019-12-31 | 26.4 | 210.5% |
2018-12-31 | 8.51 | -38.54% |
2017-12-31 | 13.8 | -135.14% |
2016-12-31 | -39.4 | -176.26% |
2015-12-31 | 51.6 | 76.05% |
2014-12-31 | 29.3 | -134.16% |
2013-12-31 | -85.9 | -654.8% |
2012-12-31 | 15.5 | -82.89% |
2011-12-31 | 90.5 | 131.13% |
2010-12-31 | 39.1 | -49.79% |
2009-12-31 | 78.0 | 162.89% |
2008-12-31 | 29.7 | 209.28% |
2007-12-31 | 9.59 | -60% |
2006-12-31 | 24.0 | 298.07% |
2005-12-31 | 6.02 | -17.52% |
2004-12-31 | 7.30 | |
2003-12-31 | N/A | |
2002-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.11 | -91.09% | ๐บ๐ธ USA |
Pfizer PFE | 1.61 | -97.19% | ๐บ๐ธ USA |
Eli Lilly LLY | 65.3 | 13.89% | ๐บ๐ธ USA |
Sanofi SNY | 1.38 | -97.60% | ๐ซ๐ท France |
Baxter BAX | 2.38 | -95.84% | ๐บ๐ธ USA |
MannKind Corp MNKD | -4.49 | -107.83% | ๐บ๐ธ USA |